Back

Safety, pharmacokinetics, and pharmacodynamics of AZD3427, a functionally selective long acting relaxin mimetic agonist of the RXFP1 receptor

20 May 2023 (14:00 - 14:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - pharmacotherapy 6 Pharmacotherapy HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Professor Marcin Ufnal

Medical University of Warsaw, Warsaw (Poland)

5 More presentations in this session

Presentation thumbnail
Total cholesterol decrease associates with higher mortality in chronic heart failure
Doctor M. Rocha (Porto, PT)
Abstract Slides
Presentation thumbnail
Hypoalbuminemia increases the time to euvolemia in heart failure patients
Doctor I. Fialho (Lisbon, PT)
Abstract Slides
Presentation thumbnail
A budget impact analysis of empagliflozin for heart failure patients with full spectrum of ejection fraction in South Korea
Doctor J. Youn (Seoul, KR)
Abstract Slides
Presentation thumbnail
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial
Doctor A. Sharma (Montreal, CA)
Abstract Slides
Presentation thumbnail
Long-acting relaxin (LY3540378) demonstrates improved renal hemodynamics response in preclinical and clinical studies
Doctor X. Wang (Indianapolis, US)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - pharmacotherapy 6

The Event

Event poster

Heart Failure 2023

20 May 2023 14:00 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources